<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Meningococcal group B vaccine (MenB-4C and MenB-FHbp): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Meningococcal group B vaccine (MenB-4C and MenB-FHbp): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Meningococcal group B vaccine (MenB-4C and MenB-FHbp): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="94522" href="/d/html/94522.html" rel="external">see "Meningococcal group B vaccine (MenB-4C and MenB-FHbp): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="99754" href="/d/html/99754.html" rel="external">see "Meningococcal group B vaccine (MenB-4C and MenB-FHbp): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F26524936"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Bexsero;</li>
<li>Trumenba</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F58686568"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Bexsero;</li>
<li>Trumenba</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F22783466"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Vaccine;</li>
<li>
                        Vaccine, Inactivated (Bacterial)</li></ul></div>
<div class="block doa drugH1Div" id="F22907273"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5689378d-786f-4432-8e79-ac04acd33191">Meningococcal group B disease prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Meningococcal group B disease prevention: Note:</b> Use of the abbreviation MenB refers to any serogroup B meningococcal conjugate vaccine; MenB-FHbp refers specifically to Trumenba; MenB-4C refers specifically to Bexsero. Products (Bexsero/Trumenba) are not interchangeable; the same product should be used for all doses in the series including booster doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33417592']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33417592'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>ACIP recommendations </i></b>
<b>
<i>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33417592']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33417592'])">Ref</a></span>):</i></b>
<b>Note:</b> Vaccines are approved in adults ≤25 years of age; however, ACIP only recommends routine vaccination of persons aged ≥10 years who are at increased risk for serogroup B meningococcal disease. In patients ≥16 years of age who are not at risk, use is per shared clinical decision-making. Consider risk of exposure and patient's susceptibility to the disease when choosing a schedule.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Patients at increased risk for serogroup B meningococcal disease or during serogroup B meningococcal disease outbreak</i>:</p>
<p style="text-indent:-2em;margin-left:8em;">Bexsero: <b>IM:</b> 0.5 mL per dose given as 2 doses ≥1 month apart. Administer a booster dose 1 year after primary series and every 2 to 3 years thereafter if risk remains. A one-time booster dose is also recommended during an outbreak if it has been ≥1 year since completion of the primary series (≥6-month interval may be considered by public health professionals).</p>
<p style="text-indent:-2em;margin-left:8em;">Trumenba: <b>IM:</b> 0.5 mL per dose given as 3-dose series at 0, 1 to 2 months, and 6 months. If the interval between the first and second dose is ≥6 months, then the third dose is not needed. If the third dose is administered &lt;4 months after the second dose, then a fourth dose should be given ≥4 months after the third dose. Administer a booster dose 1 year after primary series and every 2 to 3 years thereafter if risk remains. A one-time booster dose is also recommended during an outbreak if it has been ≥1 year since completion of the primary series (≥6-month interval may be considered by public health professionals).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Patients 16 to 23 years of age (preferred 16 to 18 years) who are </i>
<b>
<i>not</i></b>
<i> at increased risk for meningococcal disease (per shared clinical decision-making):</i>
<b> Note</b>: To provide short-term protection against most strains of serogroup B meningococcal disease:</p>
<p style="text-indent:-2em;margin-left:8em;">Bexsero: IM: 0.5 mL per dose given as 2 doses ≥1 month apart.</p>
<p style="text-indent:-2em;margin-left:8em;">Trumenba: IM: 0.5 mL per dose given as 2 doses 6 months apart. If the second dose is given earlier than 6 months, a third dose should be administered ≥4 months after the second dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>NACI recommendations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NACI.1','lexi-content-ref-NACI.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NACI.1','lexi-content-ref-NACI.2'])">Ref</a></span>): </b></i>
<b>Note: </b>Vaccines are approved in adults ≤25 years of age; however, NACI recommends consideration for vaccination of any adults who are at high risk for serogroup B meningococcal disease. Consider risk of exposure and patient's susceptibility to the disease when choosing a schedule.</p>
<p style="text-indent:-2em;margin-left:6em;">Bexsero:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Patients at high risk for serogroup B meningococcal disease or healthy patients ≤24 years of age who are <b>not</b> at high risk for meningococcal disease (per clinical discretion): </i>IM: 0.5 mL per dose given as a 2-dose series ≥4 weeks apart.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Close contacts and outbreak control of meningococcal serogroup B disease: </i></p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Unvaccinated:</i> IM: 0.5 mL immediately after exposure; revaccinate with a single dose ≥4 weeks after first dose.</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Previously vaccinated:</i> IM: 0.5 mL immediately after exposure.</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Booster dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bexsero.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bexsero.2'])">Ref</a></span>):</i> Consider a single booster dose for those individuals at continued risk of exposure to meningococcal disease as per current guideline recommendations.</p>
<p style="text-indent:-2em;margin-left:6em;">Trumenba:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Patients with underlying medical conditions at higher risk for serogroup B meningococcal disease if exposed:</i> IM: 0.5 mL per dose administered as a 3-dose series at 0, 1 to 2 months, and 6 months.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Patients at higher risk of exposure to serogroup B meningococcal disease or healthy patients ≤25 years of age who are </i>
<b>
<i>not</i></b>
<i> at high risk for meningococcal disease (per clinical discretion):</i> IM: 0.5 mL per dose given as 2-dose series 6 months apart.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991607"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. </p></div>
<div class="block doha drugH1Div" id="F50988842"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dop drugH1Div" id="F24034478"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="99754" href="/d/html/99754.html" rel="external">see "Meningococcal group B vaccine (MenB-4C and MenB-FHbp): Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5689378d-786f-4432-8e79-ac04acd33191">Meningococcal group B disease prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Meningococcal group B disease prevention: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Products (Bexsero/Trumenba) are not interchangeable; the same product should be used for all doses in the series. Use of the abbreviation MenB refers to any serogroup B meningococcal conjugate vaccine; MenB-FHbp refers specifically to Trumenba; MenB-4C refers specifically to Bexsero. Consult CDC/ACIP annual immunization schedules or National Advisory Committee on Immunization (NACI) guidelines (Canada) for additional information including specific detailed recommendations for catch-up scenarios and/or care of patients with high-risk conditions. According to ACIP, doses administered ≤4 days before minimum interval or age are considered valid; however, local or state mandates may supersede this timeframe (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kroger.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kroger.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<span style="text-decoration: underline">ACIP Recommendations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33417592']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33417592'])">Ref</a></span>):</span> Although FDA approved in children and adolescents ≥10 years, use in patients 10 to 15 years of age who are <b>not</b> at risk for infection is <b>not </b>recommended. In patients ≥16 years of age who are <b>not</b> at risk, use is per shared clinical decision making. For children ≥10 years and adolescents, ACIP recommends vaccination in patients at increased risk for serogroup B meningococcal disease, including those with persistent complement component deficiencies, who are taking complement inhibitors (eg, eculizumab, ravulizumab), with anatomic or functional asplenia (including sickle cell disease), or identified to be at increased risk due to an outbreak.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Patients at increased risk for serogroup B meningococcal disease or during serogroup B meningococcal disease outbreak</i>:</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥10 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:10em;">Primary vaccination:</p>
<p style="text-indent:-2em;margin-left:12em;">Bexsero: IM: 0.5 mL per dose for a total of 2 doses administered at least 1 month apart.</p>
<p style="text-indent:-2em;margin-left:12em;">Trumenba: IM: 0.5 mL per dose given as 3-dose series at 0, 1 to 2 months, and 6 months. If the interval between the first and second dose is ≥6 months, then the third dose is not needed. If the third dose is administered &lt;4 months after the second dose, then a fourth dose should be given ≥4 months after the third dose.</p>
<p style="text-indent:-2em;margin-left:10em;">Booster: Administer a booster dose 1 year after primary series and every 2 to 3 years thereafter if risk remains. A one-time booster dose is also recommended during an outbreak if it has been ≥1 year since completion of the primary series (≥6-month interval may be considered by public health professionals).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Patients not at increased risk (per shared clinical decision-making):</i>
<b>Note:</b> To provide short-term protection against most strains of serogroup B meningococcal disease:</p>
<p style="text-indent:-2em;margin-left:8em;">Adolescents ≥16 years:</p>
<p style="text-indent:-2em;margin-left:10em;">Bexsero: IM: 0.5 mL per dose given as 2 doses ≥1 month apart.</p>
<p style="text-indent:-2em;margin-left:10em;">Trumenba: IM: 0.5 mL per dose given as 2 doses 6 months apart. If the second dose is given earlier than 6 months, a third dose should be administered ≥4 months after the second dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<span style="text-decoration: underline">NACI recommendations and Canadian labeling (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NACI.1','lexi-content-ref-NACI.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NACI.1','lexi-content-ref-NACI.2'])">Ref</a></span>):</span></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Patients at high risk for serogroup B meningococcal disease or healthy patients who are <b>not</b> at high risk for meningococcal disease (per clinical discretion)</i>
<i>:</i> Consider risk of exposure and patient's susceptibility to the disease when choosing a schedule.</p>
<p style="text-indent:-2em;margin-left:8em;">Bexsero:</p>
<p style="text-indent:-2em;margin-left:10em;">Infants 2 to 5 months: IM:</p>
<p style="text-indent:-2em;margin-left:12em;">3-dose primary infant series: Total of 4 doses (0.5 mL each); a primary infant series is administered at 2, 4, and 6 months of age followed by a booster dose between 12 to 23 months of age; alternatively, may give first 3 doses at 2, 3, and 4 months of age; however, the immune response to 1 component (NHBA) of the vaccine is reduced with this regimen.</p>
<p style="text-indent:-2em;margin-left:12em;">2-dose primary infant series: Total of 3 doses (0.5 mL each) with first and second dose administered at least 2 months apart; followed by a booster dose between 12 to 23 months of age.</p>
<p style="text-indent:-2em;margin-left:10em;">Infants 6 months to &lt;12 months (unvaccinated): IM: Total of 3 doses (0.5 mL each) with first and second dose administered at least 2 months apart; third dose is administered during second year of life at least 2 months after the second dose. The necessity of further booster doses has not yet been determined.</p>
<p style="text-indent:-2em;margin-left:10em;">Children ≥1 year to &lt;2 years of age (unvaccinated): IM: Total of 3 doses (0.5 mL each) with first and second dose administered at least 2 months apart; third dose is administered 12 to 23 months after the second dose. The necessity of further booster doses has not yet been determined.</p>
<p style="text-indent:-2em;margin-left:10em;">Children ≥2 years and Adolescents: IM: Total of 2 doses (0.5 mL each) administered at least 1 month apart. Consider a single booster dose for those individuals at continued risk of exposure to meningococcal disease as per current guideline recommendations.</p>
<p style="text-indent:-2em;margin-left:8em;">Trumenba: Children ≥10 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Patients at increased risk for meningococcal serogroup B disease:</i> IM: 0.5 mL per dose as a 3-dose series with dose 1 and 2 separated by ≥1 month, followed by a third dose administered ≥4 months after the second dose.</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Patients not at increased risk (ie, use per clinical discretion): </i>IM: 0.5 mL per dose as a 2-dose series administered 6 months apart (eg, a 0- and 6-month schedule).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Close contacts and outbreak control of meningococcal serogroup B disease: </i>Consider risk of exposure and patient's susceptibility to the disease when choosing a schedule.</p>
<p style="text-indent:-2em;margin-left:8em;">Infants 2 months to &lt;6 months: Bexsero:</p>
<p style="text-indent:-2em;margin-left:10em;">Unvaccinated: IM: 0.5 mL immediately after exposure; revaccinate with 2 additional doses with ≥4 week interval between doses.</p>
<p style="text-indent:-2em;margin-left:10em;">Previously vaccinated: IM: 0.5 mL immediately after exposure.</p>
<p style="text-indent:-2em;margin-left:8em;">Infants 6 months to Children &lt;10 years: Bexsero:</p>
<p style="text-indent:-2em;margin-left:10em;">Unvaccinated: IM: 0.5 mL immediately after exposure; revaccinate with a single dose ≥8 weeks after first dose.</p>
<p style="text-indent:-2em;margin-left:10em;">Previously vaccinated: IM: 0.5 mL immediately after exposure.</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥10 years and Adolescents: Bexsero, Trumenba:</p>
<p style="text-indent:-2em;margin-left:10em;">Unvaccinated: IM: 0.5 mL immediately after exposure; revaccinate with a single dose ≥4 weeks after first dose.</p>
<p style="text-indent:-2em;margin-left:10em;">Previously vaccinated: IM: 0.5 mL immediately after exposure. <b>Note:</b> Product used for previous doses should be used.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51129255"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51129256"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F24526119"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequencies reported may include concomitant administration with other vaccines. Adverse reactions reported in children, adolescents, and adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (8% to 13%; severe diarrhea: &lt;1%), nausea (18% to 24%; severe nausea: 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Erythema at injection site (12% to 50%), induration at injection site (28% to 32%), pain at injection site (76% to 90%), swelling at injection site (14% to 18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chills (12% to 25%), fatigue (35% to 54%; severe fatigue: 2% to 6%), headache (33% to 52%; severe headache: 1% to 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (13% to 22%; severe arthralgia: ≤2%), myalgia (16% to 49%; severe myalgia: ≤13%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Vomiting (2% to 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Nasopharyngitis (≥2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (1% to 7%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarking:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Syncope, vasodepressor syncope</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Injection site blister formation, skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Lymphadenopathy</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection site nodule</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Swelling of eye</p></div>
<div class="block coi drugH1Div" id="F22783352"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Severe hypersensitivity to the meningococcal group B vaccine or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F22906405"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Concerns related to adverse effects:</b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use (ACIP [Kroger 2021]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Shoulder injury related to vaccine administration: Vaccine administration that is too high on the upper arm may cause shoulder injury (eg, shoulder bursitis, tendinopathy) resulting in shoulder pain and reduced range of motion following injection. Use proper injection technique for vaccines administered in the deltoid muscle (eg, injecting in the central, thickest part of the muscle) to reduce the risk of shoulder injury related to vaccine administration (Cross 2016; Foster 2013).</p>
<p style="text-indent:-2em;margin-left:4em;">• Syncope: Syncope has been reported with use of injectable vaccines and may result in serious secondary injury (eg, skull fracture, cerebral hemorrhage); typically reported in adolescents and young adults and within 15 minutes after vaccination. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs (ACIP [Kroger 2021]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Disease-related concerns:</b></p>
<p style="text-indent:-2em;margin-left:4em;">• Acute illness: The decision to administer or delay vaccination because of current or recent febrile illness depends on the severity of symptoms and the etiology of the disease. Defer administration in patients with moderate or severe acute illness (with or without fever); vaccination should not be delayed for patients with mild acute illness (with or without fever) (ACIP [Kroger 2021]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Bleeding disorders: Use with caution in patients with bleeding disorders (including thrombocytopenia); bleeding/hematoma may occur from IM administration; if the patient receives antihemophilia or other similar therapy, IM injection can be scheduled shortly after such therapy is administered (ACIP [Kroger 2021]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Meningococcal infections: Not to be used to treat meningococcal infections or to provide immunity against <i>N. meningitidis</i> serogroups A, C, W-135, or Y. In addition, vaccine does not provide protection against all circulating meningococcal group B strains.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Concurrent drug therapy issues:</b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anticoagulant therapy: Use with caution in patients receiving anticoagulant therapy; bleeding/hematoma may occur from IM administration; ideally, vaccinations should be administered prior to initiation of anticoagulant therapy if possible (ACIP [Kroger 2021]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Vaccines: In order to maximize vaccination rates, the ACIP recommends simultaneous administration (ie, &gt;1 vaccine on the same day at different anatomic sites) of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single clinic visit, unless contraindications exist. Because of differences in components and dosing regimen, meningococcal group B vaccines are not interchangeable (ACIP [Kroger 2021]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Special populations:</b></p>
<p style="text-indent:-2em;margin-left:4em;">• Altered immunocompetence: Patients with complement component deficiencies, anatomic or functional asplenia, and patients receiving complement inhibitors (eg, eculizumab, ravulizumab) are at an increased risk for invasive meningococcal infection, including post-vaccination. Consider deferring immunization during periods of severe immunosuppression (eg, patients receiving chemo/radiation therapy or other immunosuppressive therapy [including high-dose corticosteroids]); may have a reduced response to vaccination. In general, household and close contacts of persons with altered immunocompetence may receive all age appropriate vaccines. Inactivated vaccines should be administered ≥2 weeks prior to planned immunosuppression when feasible; inactivated vaccines administered during chemotherapy should be readministered after immune competence is regained (ACIP [Kroger 2021]; IDSA [Rubin 2014]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Apnea has occurred following intramuscular vaccine administration in premature infants; consider clinical status implications. In general, preterm infants should be vaccinated at the same chronological age as full-term infants (AAP [Saari 2003]; ACIP [Kroger 2021]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage form specific issues:</b></p>
<p style="text-indent:-2em;margin-left:4em;">• Kanamycin: May contain kanamycin.</p>
<p style="text-indent:-2em;margin-left:4em;">• Latex: <b>Note:</b> Prior to April 2023, the Bexsero prescribing information stated the product packaging contained latex. The Bexsero prescribing information approved by the FDA in April 2023 states the packaging is not made with latex. Providers should confirm if product in inventory contains latex prior to administering to patients with a latex allergy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Other warnings/precautions:</b></p>
<p style="text-indent:-2em;margin-left:4em;">• Antipyretics: Antipyretics have not been shown to prevent febrile seizures; antipyretics may be used to treat fever or discomfort following vaccination (ACIP [Kroger 2021]). One study reported that routine prophylactic administration of acetaminophen to prevent fever prior to vaccination decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula 2009).</p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Use of this vaccine for specific medical and/or other indications (eg, immunocompromising conditions, hepatic or kidney disease, diabetes) is also addressed in the annual ACIP Recommended Immunization Schedules (refer to CDC schedule for detailed information).</p>
<p style="text-indent:-2em;margin-left:4em;">• Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends on multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval. Vaccines may not be effective if administered during periods of altered immune competence (ACIP [Kroger 2021]).</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878791"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Clinical studies of infants &lt;12 months of age using a lower dosage than indicated for older children resulted in fever in most patients (90%).</p></div>
<div class="block foc drugH1Div" id="F26536174"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Prefilled Syringe, Intramuscular: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Bexsero:  (0.5 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Prefilled Syringe, Intramuscular [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Trumenba:  (0.5 mL) [contains polysorbate 80]</p></div>
<div class="block geq drugH1Div" id="F26524938"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block dinfoc drugH1Div" id="F58686569"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Suspension Prefilled Syringe, Intramuscular:</p>
<p style="text-indent:-2em;margin-left:4em;">Bexsero: (0.5 mL)</p>
<p style="text-indent:-2em;margin-left:2em;">Suspension Prefilled Syringe, Intramuscular [preservative free]:</p>
<p style="text-indent:-2em;margin-left:4em;">Trumenba: (0.5 mL) [contains polysorbate 80]</p></div>
<div class="block adm drugH1Div" id="F24034479"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IM:</b> For IM administration only, preferably into the upper deltoid region. Do not administer via IV, SubQ, or intradermal route. Do not mix with other vaccines or injections; separate needles and syringes should be used for each injection. To prevent syncope related injuries, patients should be vaccinated while seated or lying down (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kroger.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kroger.1'])">Ref</a></span>). US law requires that the date of administration, the vaccine manufacturer, lot number of vaccine, Vaccine Information Statement edition date and date it was provided, and the administering person's name, title, and address be recorded.</p>
<p style="text-indent:-2em;margin-left:2em;">For patients at risk of hemorrhage, the vaccine should be administered IM if, in the opinion of a health care provider familiar with the patient's bleeding risk, the vaccine can be administered by this route with reasonable safety. If the patient receives antihemophilia or other similar therapy, IM vaccination can be scheduled shortly after such therapy is administered. A fine needle (23-gauge or smaller) can be used for the vaccination and firm pressure applied to the site (without rubbing) for at least 2 minutes. The patient or family should be instructed concerning the risk of hematoma from the injection. Patients on anticoagulant therapy should be considered to have the same bleeding risks and treated as those with clotting factor disorders (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kroger.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kroger.1'])">Ref</a></span>).</p></div>
<div class="block admp drugH1Div" id="F52614552"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Shake vigorously to ensure that a homogenous white suspension is obtained. Do not use the vaccine if it cannot be resuspended. Administer by IM injection into upper deltoid region; not for intradermal, subcutaneous, or IV administration. Do not mix with other vaccines or injections; separate needles and syringes should be used for each injection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kroger.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kroger.1'])">Ref</a></span>). To prevent syncope related injuries, adolescents should be vaccinated while seated or lying down (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kroger.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kroger.1'])">Ref</a></span>). US law requires that the date of administration, the vaccine manufacturer, lot number of vaccine, vaccine information statement (VIS) edition date and date it was provided, and the administering person's name, title, and address be recorded.</p>
<p style="text-indent:0em;margin-top:2em;">For patients at risk of hemorrhage, the vaccine should be administered IM if, in the opinion of a physician familiar with the patient's bleeding risk, the vaccine can be administered by this route with reasonable safety. If the patient receives antihemophilia or other similar therapy, IM vaccination can be scheduled shortly after such therapy is administered. A fine needle (23-gauge or smaller) can be used for the vaccination and firm pressure applied to the site (without rubbing) for at least 2 minutes. The patient should be instructed concerning the risk of hematoma from the injection. Patients on anticoagulant therapy should be considered to have the same bleeding risks and treated as those with clotting factor disorders (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kroger.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kroger.1'])">Ref</a></span>).</p></div>
<div class="block meg drugH1Div" id="F46549865"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;">In the United States, the appropriate CDC-approved Vaccine Information Statement (VIS) must be provided to the patient/caregiver before administering each dose of this vaccine; the VIS edition date and date it was provided to the patient/caregiver should be recorded as required by US law. VIS is available at <a href="/external-redirect?target_url=http%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fhcp%2Fvis%2Fvis-statements%2Fmening-serogroup.html&amp;token=aK%2FCcoQdX%2F5TmLpK2VFkC7EF6ocC7JFwObz3NLDuW53jqgBEPnlr%2Bwol1zqTkUGfeBnplVkDAn9lTLNxrcRzY4762AEsipb4jEWBt%2BXgIU8%3D&amp;TOPIC_ID=91590" target="_blank">http://www.cdc.gov/vaccines/hcp/vis/vis-statements/mening-serogroup.html</a>.</p></div>
<div class="block use drugH1Div" id="F24034440"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Meningococcal group B disease prevention:</b></p>
<p style="text-indent:-2em;margin-left:2em;">
<i>US labeling:</i> Active immunization of children, adolescents, and adults aged 10 to 25 years against invasive meningococcal disease caused by <i>Neisseria meningitidis</i> serogroup B.</p>
<p style="text-indent:-2em;margin-left:4em;">The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination of the following persons ≥10 years of age at increased risk of meningococcal disease (CDC/ACIP [Mbaeyi 2020]):</p>
<p style="text-indent:-2em;margin-left:6em;">- Persons with complement component deficiencies (eg, C3, C5-C9, properdin, factor H, or factor D deficiencies; patients receiving complement inhibitors [eg, eculizumab, ravulizumab]).</p>
<p style="text-indent:-2em;margin-left:6em;">- Persons with anatomic or functional asplenia (including sickle cell disease).</p>
<p style="text-indent:-2em;margin-left:6em;">- Microbiologists routinely exposed to isolates of <i>N. meningitidis.</i></p>
<p style="text-indent:-2em;margin-left:6em;">- Persons identified to be at increased risk during an outbreak caused by serogroup B meningococcal disease.</p>
<p style="text-indent:-2em;margin-left:4em;">The ACIP states that a meningococcal group B vaccination series may be administered to adolescents and young adults aged 16 to 23 years as determined by shared clinical decision-making to provide short-term protection against most strains of serogroup B meningococcal disease. The preferred age for vaccination is 16 to 18 years of age (CDC/ACIP [Mbaeyi 2020]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Active immunization against invasive meningococcal disease caused by <i>N. meningitidis</i> serogroup B (Bexsero: patients 2 months through 25 years of age; Trumenba: patients 10 through 25 years of age).</p>
<p style="text-indent:-2em;margin-left:4em;">The Canadian National Advisory Committee on Immunization (NACI) recommends use of Bexsero (patients ≥2 months of age) or Trumenba (patients ≥10 years of age) in patients at high risk for serogroup B meningococcal disease (including disease outbreaks) and may be considered on an individual basis in healthy patients (Bexsero: 2 months to 25 years of age; Trumenba: 10 to 25 years of age) (NACI/CATMAT 2015; NACI 2019).</p></div>
<div class="block cyt drugH1Div" id="F22813132"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F22813129"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetaminophen: May diminish the therapeutic effect of Vaccines. Management: Consider avoiding routine prophylactic use of acetaminophen before or during vaccine administration when possible. Acetaminophen is still recommended to treat fevers and/or pain that occurs after vaccination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anti-CD20 B-Cell Depleting Therapies: May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Give inactivated vaccines at least 2 weeks prior to initiation or 6 months after anti-CD20 B-cell depleting therapies. If vaccinated prior to B cell recovery, consider assessing immune response to vaccination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Give inactivated vaccines at least 2 weeks prior to initiation of cladribine when possible. Patients vaccinated less than 14 days before initiating or during cladribine should be revaccinated at least 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Administer vaccines at least 2 weeks prior to immunosuppressive corticosteroids if possible. If patients are vaccinated less than 14 days prior to or during such therapy, repeat vaccination at least 3 months after therapy if immunocompetence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elivaldogene Autotemcel: May enhance the adverse/toxic effect of Vaccines. Specifically, there may be a greater risk for contracting an infection from any live vaccine. Elivaldogene Autotemcel may diminish the therapeutic effect of Vaccines. Management: Administration of vaccines is not recommended in the 6 weeks before myeloablative conditioning, and until hematologic recovery after elivaldogene autotemcel treatment.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting fingolimod. If vaccinated during fingolimod therapy, revaccinate 2 to 3 months after fingolimod discontinuation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Cytotoxic Chemotherapy): May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Give inactivated vaccines at least 2 weeks prior to initiation of chemotherapy when possible. Patients vaccinated less than 14 days before initiating or during chemotherapy should be revaccinated at least 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Miscellaneous Oncologic Agents): May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Give inactivated vaccines at least 2 weeks prior to initiation of immunosuppressants when possible. Patients vaccinated less than 14 days before initiating or during therapy should be revaccinated at least 3 after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Therapeutic Immunosuppressant Agents): May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Give inactivated vaccines at least 2 weeks prior to initiation of immunosuppressants when possible. Patients vaccinated less than 14 days before initiating or during therapy should be revaccinated at least 2 to 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Administer vaccines at least 2 weeks prior to methotrexate initiation, if possible. If patients are vaccinated less than 14 days prior to or during methotrexate therapy, repeat vaccination at least 3 months after therapy if immunocompetence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propacetamol: May diminish the therapeutic effect of Vaccines. Management: Consider avoiding routine prophylactic use of propacetamol before or during vaccine administration when possible. Propacetamol is still recommended to treat fevers and/or pain that occurs after vaccination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Siponimod: May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Avoid administration of vaccines (inactivated) during treatment with siponimod and for 1 month after discontinuation due to potential decreased vaccine efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teplizumab: May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Vaccination with inactivated or non-replicating vaccines is not recommended in the 2 weeks prior to teplizumab therapy, during treatment, or for 6 weeks following completion of therapy.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F22906403"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Information related to the use of meningococcal group B vaccines in pregnancy is limited (CDC/ACIP [Mbaeyi 2020]).</p>
<p style="text-indent:0em;margin-top:2em;">Inactivated vaccines have not been shown to cause increased risks to the fetus (ACIP [Kroger 2021]). However, the Advisory Committee on Immunization Practices recommends deferring meningococcal group B vaccination during pregnancy unless the patient is at increased risk for meningococcal disease and vaccination benefits outweigh the potential risks.</p></div>
<div class="block brc drugH1Div" id="F22906404"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if components of this vaccine are present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to continue or discontinue breastfeeding following immunization should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of vaccination to the mother.</p></div>
<div class="block mop drugH1Div" id="F24034480"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor for hypersensitivity and syncope for 15 minutes following administration (ACIP [Kroger 2021]). If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.</p></div>
<div class="block pha drugH1Div" id="F22907033"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:-2em;margin-left:2em;">Bexsero: Induces immunity against meningococcal disease caused by serogroup B <i>Neisseria meningitidis</i> (MenB) via the formation of antibodies directed toward the recombinant protein antigens combined together with outer membrane vesicles (OMV) from a group B strain.</p>
<p style="text-indent:-2em;margin-left:2em;">Trumenba: Protection against invasive meningococcal disease is conferred mainly by complement-mediated antibody-dependent killing of <i>N. meningitidis</i>.</p>
<p style="text-indent:-2em;margin-left:2em;">Efficacy:</p>
<p style="text-indent:-2em;margin-left:4em;">Bexsero: Composite hSBA titer response one month after the second dose: 63% to 88%</p>
<p style="text-indent:-2em;margin-left:4em;">Trumenba: 84% of adolescents had a ≥4-fold rise in hSBA titer and composite response after the third dose.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F23671423"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Bexsero</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Bexsero</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Bexsero</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Bexsero</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Bexsero</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Bexsero</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Bexsero</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Bexsero</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Bexsero</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Bexsero</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Bexsero</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Bexsero</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Bexsero</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Bexsero</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Bexsero</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Bexsero</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Bexsero</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Bexsero</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Bexsero</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Bexsero</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Bexsero</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Bexsero</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Bexsero</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Bexsero</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Bexsero</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Bexsero</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Bexsero</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Bexsero</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Bexsero</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Bexsero</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Bexsero</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Bexsero</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Bexsero</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Bexsero</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Bexsero</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Bexsero</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Bexsero</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meningococcal-group-b-vaccine-menb-4c-and-menb-fhbp-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bexsero.1">
<a name="Bexsero.1"></a>Bexsero (multicomponent meningococcal B vaccine) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; April 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bexsero.2">
<a name="Bexsero.2"></a>Bexsero (multicomponent meningococcal B vaccine) [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline Inc; March 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NACI.1">
<a name="NACI.1"></a>Canadian National Advisory Committee on Immunization (NACI), Committee to Advise on Tropical Medicine and Travel (CATMAT). Meningococcal vaccine. Canadian Immunization Guide. <a href="https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-13-meningococcal-vaccine.html" target="_blank">https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-13-meningococcal-vaccine.html</a>. Updated May 2015. Accessed August 24, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NACI.2">
<a name="NACI.2"></a>Canadian National Advisory Committee on Immunization (NACI). The use of bivalent factor H binding protein meningococcal serogroup B (MenB-fHBP) vaccine for the prevention of meningococcal B disease. <a href="https://www.canada.ca/en/public-health/services/publications/vaccines-immunization/bivalent-factor-h-binding-protein-meningococcal-serogroup-b-prevention-meningococcal-b-disease.html" target="_blank">https://www.canada.ca/en/public-health/services/publications/vaccines-immunization/bivalent-factor-h-binding-protein-meningococcal-serogroup-b-prevention-meningococcal-b-disease.html</a>. Published December 24, 2019. Accessed March 6, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meningococcal-group-b-vaccine-menb-4c-and-menb-fhbp-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.1">
<a name="CDC.1"></a>Centers for Disease Control and Prevention (CDC). Serogroup B Meningococcal Vaccine Questions and Answers. <a href="https://www.cdc.gov/meningococcal/vaccine-serogroupB.html#serogroup" target="_blank">http://www.cdc.gov/meningococcal/vaccine-serogroupB.html#serogroup</a>. Accessed March 7, 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.2">
<a name="CDC.2"></a>Centers for Disease Control and Prevention (CDC). Vaccination guidance during a pandemic. Updated October 20, 2020. Available at <a href="https://www.cdc.gov/vaccines/pandemic-guidance/index.html" target="_blank">https://www.cdc.gov/vaccines/pandemic-guidance/index.html</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27166466">
<a name="27166466"></a>Cross GB, Moghaddas J, Buttery J, Ayoub S, Korman TM. Don't aim too high: avoiding shoulder injury related to vaccine administration. <i>Aust Fam Physician</i>. 2016;45(5):303-306.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meningococcal-group-b-vaccine-menb-4c-and-menb-fhbp-drug-information/abstract-text/27166466/pubmed" id="27166466" target="_blank">27166466</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23636163">
<a name="23636163"></a>Foster SL, Davis MV. Vaccine administration: preventing serious shoulder injuries. <i>J Am Pharm Assoc (2003)</i>. 2013;53(1):102-103. doi:10.1331/JAPhA.2013.13503<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meningococcal-group-b-vaccine-menb-4c-and-menb-fhbp-drug-information/abstract-text/23636163/pubmed" id="23636163" target="_blank">23636163</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22318278">
<a name="22318278"></a>Gossger N, Snape MD, Ly-Mee Y, et al, Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. <i>JAMA</i>. 2012;307(6):573-582.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meningococcal-group-b-vaccine-menb-4c-and-menb-fhbp-drug-information/abstract-text/22318278/pubmed" id="22318278" target="_blank">22318278</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313..<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meningococcal-group-b-vaccine-menb-4c-and-menb-fhbp-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kroger.1">
<a name="Kroger.1"></a>Kroger A, Bahta L, Hunter P. General best practice guidelines for immunization: best practices guidance of the Advisory Committee on Immunization Practices (ACIP). <a href="https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf" target="_blank">https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf</a>. Accessed April 30, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meningococcal-group-b-vaccine-menb-4c-and-menb-fhbp-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33417592">
<a name="33417592"></a>Mbaeyi SA, Bozio CH, Duffy J, et al. Meningococcal vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020. <i>MMWR Recomm Rep</i>. 2020;69(9):1-41.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meningococcal-group-b-vaccine-menb-4c-and-menb-fhbp-drug-information/abstract-text/33417592/pubmed" id="33417592" target="_blank">33417592</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19837254">
<a name="19837254"></a>Prymula R, Siegrist CA, Chlibek R, et al. Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials. <i>Lancet</i>. 2009;374(9698):1339-1350.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meningococcal-group-b-vaccine-menb-4c-and-menb-fhbp-drug-information/abstract-text/19837254/pubmed" id="19837254" target="_blank">19837254</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24311479">
<a name="24311479"></a>Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. <i>Clin Infect Dis</i>. 2014;58(3):e44-e100.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meningococcal-group-b-vaccine-menb-4c-and-menb-fhbp-drug-information/abstract-text/24311479/pubmed" id="24311479" target="_blank">24311479</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12837889">
<a name="12837889"></a>Saari TN; American Academy of Pediatrics Committee on Infectious Diseases. Immunization of preterm and low birth weight infants. <i>Pediatrics</i>. 2003;112(1, pt 1):193-198. doi:10.1542/peds.112.1.193<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meningococcal-group-b-vaccine-menb-4c-and-menb-fhbp-drug-information/abstract-text/12837889/pubmed" id="12837889" target="_blank">12837889</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meningococcal-group-b-vaccine-menb-4c-and-menb-fhbp-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Trumenba.1">
<a name="Trumenba.1"></a>Trumenba (meningococcal group B vaccine) [prescribing information]. Philadelphia, PA; Wyeth Pharmaceuticals LLC; August 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Trumenba.2">
<a name="Trumenba.2"></a>Trumenba (meningococcal group B vaccine) [prescribing information]. Philadelphia, PA; Wyeth Pharmaceuticals LLC; November 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Trumenba.3">
<a name="Trumenba.3"></a>Trumenba (meningococcal group B vaccine) [product monograph]. Kirkland, Quebec, Canada; Pfizer Canada ULC; October 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23324563">
<a name="23324563"></a>Vesikari T, Esposito S, Prymula R, et al. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. <i>Lancet</i>. 2013;381(9869):825-835.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meningococcal-group-b-vaccine-menb-4c-and-menb-fhbp-drug-information/abstract-text/23324563/pubmed" id="23324563" target="_blank">23324563</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Guiding principles for immunization activities during the COVID-19 pandemic: interim guidance, 26 March 2020. Published March 26, 2020. Available at https://apps.who.int/iris/handle/10665/331590
                  </div>
</li></ol></div><div id="topicVersionRevision">Topic 91590 Version 215.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
